Mild Cognitive Impairment – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mild Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions.
Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol.
The Mild Cognitive Impairment drugs in development market research report provide comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mild Cognitive Impairment | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 49 molecules, with 46 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mild Cognitive Impairment therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mild Cognitive Impairment pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mild Cognitive Impairment treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Actinogen Medical LtdAcumen Pharmaceuticals Inc
Addex Therapeutics Ltd
AgeneBio Inc
Amylyx Pharmaceuticals Inc
ANLBio Co Ltd
Araclon Biotech SL
AriBio Co Ltd
Biomed Industries Inc
BioVie Inc
CereSpir Inc
Chang Gung Memorial Foundation
Cognigenics Inc
CuraSen Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Filament Health Corp
FUJIFILM Toyama Chemical Co Ltd
Gray Matter
Grespo AB
ImmunoChem Therapeutics LLC
Innovation Pathways LLC
IntelGenx Corp
Jupiter Neurosciences Inc
KeifeRx LLC
Merck & Co Inc
NeurAegis Inc
Neuraly Inc
NKGen Biotech Inc
Novartis AG
Novo Nordisk AS
Oligomerix inc
Pfizer Inc
ProNeurogen Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
SciSparc Ltd
Shackelford Pharma Inc
SinoMab Bioscience Ltd
TauRx Therapeutics Ltd
Thomas Jefferson University
UCB SA
University of California
Vandria SA
Vivoryon Therapeutics NV
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mild Cognitive Impairment reports